Variational AI

Hit ID and Hit-to-lead: two of the most resource-intensive stages in small molecule discovery. Stages Enki™ 4 is designed to eliminate. "Enki 4 enables our biotech partners to start with novel leads they would not have discovered using traditional methods. Our goal is to eliminate hit ID and hit-to-lead, generating molecules ready to go directly into lead optimization." — Handol Kim, Co-Founder & CEO With Enki™ 4, Variational AI is expanding the pre-trained target coverage from 592 to 760 and extend the modality capabilities to degraders, PROTACs, molecular glues, and ADC payloads. Read the official press release: https://lnkd.in/g5Fp7EUK #AIDD #DrugDiscovery #GenerativeAI #SmallMolecules #GenAIinPharma #Enki4 #VariationalAI

We just released Enki™ 4 🚀 A major update to our generative AI foundation model for small-molecule drug discovery. What's new? → 760 pre-trained drug targets (up from 592), with more to be released soon → Enhanced performance across 12+ target classes including GPCRs, kinases, ion channels, proteases, oxidoreductases, hydrolases, and others → Now applicable to proximity-based therapeutics and novel payloads for antibody drug conjugates → Re-architected platform designed to scale Our goal with Enki™ 4 is to eliminate hit ID and hit-to-lead, generating molecules ready to go directly into lead optimization. Learn more about Enki™ 4 now: https://lnkd.in/gnDx5N9D #Enki4 #DrugDiscovery #GenerativeAI #Biotech #AIinPharma #SmallMolecule #VariationalAI

Enki™ combines curated public data, proprietary generative models, and partner datasets. In collaboration with Merck, it will generate and optimize small-molecule candidates against two designated targets.

Variational AI is collaborating with Merck (MSD) to apply Enki™ in the design of novel small molecules for two designated targets. A deal worth up to USD $349 million in potential value.

We’ve entered a collaboration with Merck (MSD) to apply our Enki™ platform—fine-tuned on Merck’s proprietary data—to generate and optimize novel small-molecule candidates. Merck holds exclusive rights to develop and commercialize resulting compounds.

Merck and Variational AI have entered a collaboration to apply Enki™ to two therapeutic targets. The goal: generate and optimize novel small molecules with improved probability of success earlier in the discovery continuum.